Chikungunya vaccine candidate safe and immunogenic in Phase III
Synopsis : Valneva’s single-shot chikungunya vaccine candidate, VLA1553, offered a very high level of seroprotection in all adults, including the elderly. The…
Synopsis : Valneva’s single-shot chikungunya vaccine candidate, VLA1553, offered a very high level of seroprotection in all adults, including the elderly. The…
Summary : The Committee for Medicinal Products for Human Use (CHMP) has provided an initial assessment of Valneva’s inactivated, adjuvanted COVID-19 vaccine…
Summary : The success of mRNA vaccines against COVID-19 has become a cash cow for Moderna, the Pfizer and BioNTech team and…
Although fractures normally heal, bone will not regenerate under several circumstances. When bone does not regenerate, major clinical problems could result, including…
Summary : A study in monkeys pitting the current Moderna Inc (MRNA.O) COVID-19 booster against an Omicron-specific booster showed no significant differences…
Uppsala researchers have succeeded in designing a molecule that inhibits the replication of coronaviruses and that has great potential for development into…
Synopsis : Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the initiation of a clinical study to evaluate the safety,…
Synopsis: Pfizer’s JAK inhibitor Xeljanz and Novartis’ S1P modulator Gilenya both have their share of safety problems. But Vyne Therapeutics thinks it…
Summary : AstraZeneca has completed the transfer of its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and…
Summary : -Abbott, a global healthcare leader, announced that the US Food and Drug Administration (FDA) has approved new expanded magnetic resonance…